Literature DB >> 31630730

FDG-PET Imaging in Cervical Cancer.

Nemi Gandy1, Mubarik A Arshad1, Won-Ho E Park2, Andrea G Rockall3, Tara D Barwick4.   

Abstract

FDG-PET/CT has an established role in the initial staging of locally advanced cervical cancers, particularly in evaluation of nodal disease and distant metastases. It is common practice to perform FDG-PET/CT 3 months postcompletion of chemoradiotherapy as it can predict outcome and be used to tailor management, including adjuvant therapy and follow-up. It is also routinely used prior to pelvic exenterative surgery to ensure there is no disease outside the pelvis. There is growing evidence that FDG-PET-derived parameters are prognostic and could potentially be used to tailor therapy. This review outlines the use of FDG-PET/CT imaging in cervical cancer. Crown
Copyright © 2019. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31630730     DOI: 10.1053/j.semnuclmed.2019.06.007

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  9 in total

Review 1.  PET-CT in Clinical Adult Oncology-IV. Gynecologic and Genitourinary Malignancies.

Authors:  Ahmed Ebada Salem; Gabriel C Fine; Matthew F Covington; Bhasker R Koppula; Richard H Wiggins; John M Hoffman; Kathryn A Morton
Journal:  Cancers (Basel)       Date:  2022-06-18       Impact factor: 6.575

2.  Predictive value of preoperative serum squamous cell carcinoma antigen level for lymph node metastasis in early-stage cervical squamous cell carcinoma.

Authors:  Chenggong Zhu; Wenqing Zhang; Xiuying Wang; Lanzhou Jiao; Liyan Chen; Jiyong Jiang
Journal:  Medicine (Baltimore)       Date:  2021-08-20       Impact factor: 1.817

3.  Evaluation of an Automatic Classification Algorithm Using Convolutional Neural Networks in Oncological Positron Emission Tomography.

Authors:  Pierre Pinochet; Florian Eude; Stéphanie Becker; Vijay Shah; Ludovic Sibille; Mathieu Nessim Toledano; Romain Modzelewski; Pierre Vera; Pierre Decazes
Journal:  Front Med (Lausanne)       Date:  2021-02-26

Review 4.  A Review of Nuclear Medicine Approaches in the Diagnosis and the Treatment of Gynecological Malignancies.

Authors:  Nasim Vahidfar; Saeed Farzanefar; Hojjat Ahmadzadehfar; Eóin N Molloy; Elisabeth Eppard
Journal:  Cancers (Basel)       Date:  2022-03-31       Impact factor: 6.639

Review 5.  Quantitative imaging of uterine cancers with diffusion-weighted MRI and 18-fluorodeoxyglucose PET/CT.

Authors:  Madeleine Sertic; Aoife Kilcoyne; Onofrio Antonio Catalano; Susanna I Lee
Journal:  Abdom Radiol (NY)       Date:  2021-07-23

6.  Correlation between hematological parameters and outcome in patients with locally advanced cervical cancer treated by concomitant chemoradiotherapy.

Authors:  Christine Gennigens; Marjolein De Cuypere; Laurence Seidel; Johanne Hermesse; Annelore Barbeaux; Frédéric Forget; Adelin Albert; Guy Jerusalem; Frédéric Kridelka
Journal:  Cancer Med       Date:  2020-09-20       Impact factor: 4.452

7.  A Unique Finding of Hepatogastric Fistula in Cervical Cancer Liver Metastasis.

Authors:  Sankar Narayanan; Pottakkat Biju; Senthamizhan Sundaramoorthy; Vishnukumar Rajaraman; Sreerekha Jinkala
Journal:  Cureus       Date:  2021-12-27

8.  18F-FDG PET/computed tomography scan in patients with suspicion of recurrent neuroendocrine carcinoma of the cervix.

Authors:  Yuanyuan Jiang; Guozhu Hou; Li Huo; Fang Li; Zhaohui Zhu; Wuying Cheng
Journal:  Nucl Med Commun       Date:  2021-10-01       Impact factor: 1.690

9.  [18F]FDG PET radiomics to predict disease-free survival in cervical cancer: a multi-scanner/center study with external validation.

Authors:  Marta Ferreira; Pierre Lovinfosse; Johanne Hermesse; Marjolein Decuypere; Caroline Rousseau; François Lucia; Ulrike Schick; Caroline Reinhold; Philippe Robin; Mathieu Hatt; Dimitris Visvikis; Claire Bernard; Ralph T H Leijenaar; Frédéric Kridelka; Philippe Lambin; Patrick E Meyer; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-03-26       Impact factor: 9.236

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.